Basal cell carcinoma (BCC) is a common type of skin cancer that can be challenging to treat in advanced stages. Join Karl Lewis, MD, and Aleksandar Sekulic, MD, PhD, as they discuss the importance of the hedgehog pathway in the pathogenesis of BCC and the role of hedgehog inhibitors in advanced BCC. Evidence related to the safety and efficacy of the approved hedgehog inhibitors sonidegib and vismodegib is discussed, with recommendations for optimizing their use. Case studies are utilized to share the faculty’s experience in treating patients with hedgehog inhibitors, including strategies to manage resistance.

As in medicine generally, the management of patients with locally advanced basal cell carcinoma is rapidly evolving. To help clinicians keep abreast of new information, this CME activity will be updated 4 times through October 2021. The first update included new information released between February 17, 2021, and April 7, 2021. The second update includes new information released between April 8, 2021, and June 1, 2021. The third update includes new information released between June 1, 2021, and July 30, 2021.The fourth update includes new information published between August 1, 2021, and September 30, 2021.

Presenting Faculty

• 

  Karl D. Lewis, MD

  Associate Professor of Medicine
  Division of Medical Oncology
  University of Colorado
  Medical Oncologist
  UCH - Cancer Center
  Aurora, Colorado

• 

  Aleksandar Sekulic, MD, PhD

  Deputy Director, Mayo Clinic Cancer Center
  Associate Director, Center for Individualized Medicine
  Vice Chair, Department of Dermatology
  Chair, Cutaneous Oncology Disease Group
  Mayo Clinic Scottsdale
  Scottsdale, Arizona